Pharma Mar SA (PHMMF)
87.58
0.00 (0.00%)
USD |
OTCM |
Aug 21, 16:00
Pharma Mar 1 Year Total Returns (Daily) : -8.33% for Aug. 21, 2026
1 Year Total Returns (Daily) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical 1 Year Total Returns (Daily) Data
| Date | Value |
|---|---|
| August 21, 2026 | -8.33% |
| August 20, 2026 | -8.33% |
| August 19, 2026 | -8.33% |
| August 18, 2026 | -8.33% |
| August 17, 2026 | -8.33% |
| August 14, 2026 | -8.33% |
| August 13, 2026 | -8.33% |
| August 12, 2026 | -2.83% |
| August 11, 2026 | -2.83% |
| August 10, 2026 | -2.83% |
| August 07, 2026 | -2.83% |
| August 06, 2026 | -2.83% |
| August 05, 2026 | -2.83% |
| August 04, 2026 | -4.49% |
| August 03, 2026 | -4.49% |
| July 31, 2026 | -4.49% |
| July 30, 2026 | -4.49% |
| July 29, 2026 | -4.49% |
| July 28, 2026 | -8.14% |
| July 27, 2026 | -5.88% |
| July 24, 2026 | -5.88% |
| July 23, 2026 | -5.88% |
| July 22, 2026 | -5.88% |
| July 21, 2026 | -5.88% |
| July 20, 2026 | -5.88% |
| Date | Value |
|---|---|
| July 17, 2026 | -5.88% |
| July 16, 2026 | -5.88% |
| July 15, 2026 | -5.88% |
| July 14, 2026 | -5.88% |
| July 13, 2026 | -0.62% |
| July 10, 2026 | -0.62% |
| July 09, 2026 | 3.14% |
| July 08, 2026 | 3.14% |
| July 07, 2026 | -14.13% |
| July 06, 2026 | -14.13% |
| July 02, 2026 | -14.13% |
| July 01, 2026 | -14.13% |
| June 30, 2026 | -14.13% |
| June 29, 2026 | -14.13% |
| June 26, 2026 | -14.13% |
| June 25, 2026 | -14.13% |
| June 24, 2026 | -13.28% |
| June 23, 2026 | -13.28% |
| June 22, 2026 | -14.42% |
| June 18, 2026 | -23.17% |
| June 17, 2026 | -23.17% |
| June 16, 2026 | -23.17% |
| June 15, 2026 | -23.17% |
| June 12, 2026 | -23.17% |
| June 11, 2026 | 2.91% |
Total Return Definition
The Total return is the change in price over a specific period of time that includes dividends and distributions paid.
1 Year Total Returns (Daily) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
1 Year Total Returns (Daily) Benchmarks
| Oryzon Genomics SA | 2.44% |
| Grifols SA | -19.46% |
| ACADIA Pharmaceuticals, Inc. | 19.02% |
| Alkermes Plc | 66.31% |
| Alnylam Pharmaceuticals, Inc. | -49.48% |